December 02, 2025

To,	То,
National Stock Exchange of India Limited	BSE Limited
Exchange Plaza, C-1,	Phiroze Jeejeebhoy Towers,
Block G, Bandra Kurla Complex,	Dalal Street, Mumbai- 400001
Bandra (E), Mumbai – 400 051	
То,	
Thyrocare Technologies Limited	
D37/3, TTC MIDC, Turbhe, Navi Mumbai - 400	0 073

Sub: Disclosure under Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers)
Regulations, 2011 – Encumbrance on Bonus Shares Allotted by Thyrocare Technologies Limited

Dear Sir/Madam,

We hereby inform you that **Docon Technologies Private Limited** ("Docon"), a wholly owned subsidiary of **API Holdings Limited** ("API") and a Promoter & Holding Company of **Thyrocare Technologies Limited** ("Thyrocare"), is submitting the enclosed disclosure under **Regulation 29(2)** of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011.

Thyrocare allotted **Bonus Shares on December 01, 2025**, in the ratio of **2:1** (two new bonus equity shares of face value ₹10 each, fully paid-up, for every one existing equity share of face value ₹10 each, fully paid-up, held by the beneficial holders on the Record Date i.e. November 28, 2025).

Pursuant to the bonus allotment, fresh encumbrance has been created on the bonus equity shares allotted to Docon against its existing shareholding ("Bonus Shares"). The pledge is created by Docon in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee, to secure the obligations of API Holdings Limited in respect of the secured, unlisted, redeemable non-convertible debentures issued by API.

While the number of shares encumbered by Docon has increased, the percentage of encumbered shareholding remains unchanged at 60.93% of the total paid-up equity share capital of Thyrocare.

The details are as under:

Particulars	Before Bonus Allotment	Fresh Encumbrance on Bonus Shares	After Bonus Allotment
No. of shares encumbered	3,23,23,232	6,46,46,464	9,69,69,696
% of total share capital of Thyrocare	60.93%	60.93%*	60.93%

^{*}Represents pledge on 60.93% of the Bonus Shares allotted.

The above represents fresh creation of encumbrance only on the Bonus Shares, and there is no change in the percentage of promoter shareholding or percentage of encumbered shares.

In compliance with Regulation 29(2) of the SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011 and the SEBI Master Circular SEBI/HO/CFD/PoD-1/P/CIR/2023/31 dated February 16, 2023, we are submitting herewith the disclosure in the prescribed format as an Annexure I,

reflecting the encumbrance created on the Bonus Shares.

You are requested to kindly take the same on record.

For Docon Technologies Private Limited

Madhuri Sudhir Sarangdha

Company Secretary

Membership no. A36893 Date: December 02, 2025

Annexure I

Disclosures under Regulation 29(2) of Securities and Exchange Board of India (Substantial Acquisition of Shares and Takeovers) Regulations, 2011

Name of the Target Company (TC)	Thyrocare Technologies Limited ('Thyrocare")		
Name(s) of the acquirer and Persons Acting in Concert (PAC) with the acquirer	Pledgor: Docon Technologies Private Limited ("Docon" / "Pledgor"), which has created a pledgo over the Bonus Shares in favour of Catalys Trusteeship Limited, acting as Debenture Trustee on behalf of the debenture holders of API.		
Whether the acquirer belongs to Promoter/Promoter group	Yes		
Name(s) of the Stock Exchange(s) where the shares of TC are Listed	BSE Limited National Stock Exchange of India Limited		
Details of the acquisition / disposal as follows	Number	% w.r.t. total share /voting capital wherever applicable (*)	% w.r.t. total diluted share/votin g capital of the TC (**)
Before the acquisition under consideration, holding of:			
 Shares carrying voting rights 	NIL	NiL	NIL
 Shares in the nature of encumbrance (pledge / lien/-non-disposal undertaking/others) 	3,23,23,232	60.93	60.73
c. Voting rights (VR) otherwise than by shares	NIL	NIL	NIL
 d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) 	NIL	NIL .	NIL
e. Total (a+b+c+d)	3,23,23,232	60.93	60.73
etails of acquisition/sale			
a. Shares carrying voting rights acquired/sold	Nil	Nil	Ni
b. VRs acquired /sold otherwise than by shares	Nil	Nil	Ni
c. Warrants/convertible securities/any other	Nil	Nil	Ni
d. instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category)	6,46,46,464	60.93#	60.73

acquired/sold Shares encumbered / invoked/released by the acquirer)			
e. Total (a+b+c+/-d)	6,46,46,464	60.93	60.73
After the acquisition/sale, holding of:			
a. Shares carrying voting rights	Nil	Nil	Nil
b. Shares encumbered with the acquirer	9,69,69,696	60.93	60.73
c. VRs otherwise than by shares	Nil	Nil	Nil
 d. Warrants/convertible securities/any other instrument that entitles the acquirer to receive shares carrying voting rights in the TC (specify holding in each category) after acquisition 	Nil	Nil	Nil
e. Total (a+b+c+d)	9,69,69,696	60.93	60.73
Mode of acquisition / sale (e.g. open market / off-market / public issue / rights issue / preferential allotment / inter-se transfer etc).	Fresh creation of pledge on 6,46,46,464 Bonus Shares issued and allotted by Thyrocare Technologies Limited, created by Docon in favour of Catalyst Trusteeship Limited, acting as Debenture Trustee, to secure the obligations of API Holdings Limited in respect of the secured, unlisted, redeemable non-convertible debentures issued by API.		
Date of acquisition / sale of shares / VR or date of receipt of intimation of allotment of shares, whichever is applicable	December 02,20	25	
Equity share capital / total voting capital of the TC before the said acquisition / sale	Total equity share capital of the Target Company: 15,91,61,691 equity shares of ₹10 each.		
Equity share capital/total voting capital of the TC after the said acquisition / sale	Shares encumber	ered post Bonus Shar	es pledge: A
Total diluted share/voting capital of the TC after the said acquisition	total of 9,69,69,696 equity shares of ₹10 each, including a fresh pledge created on 6,46,46,464 Bonus Equity Shares.		

(*) Total share capital/voting capital to be taken as per the latest filing done by the company to the Stock Exchange under Clause 35 of the listing Agreement.

(**) Diluted share/voting capital means the total number of shares in the TC assuming full conversion of the outstanding convertible securities/warrants into equity shares of the TC.

(#) Represents pledge on 60.93% of the Bonus Shares allotted.

For and on behalf of Docon Technologies Private Limited

Madhuri Sudhir Sarangdhar

Company Secretary
Membership no. A36893

Date: December 02, 2025